LUCID DIAGNOSTICS INC. Financials Lucid Diagnostics Inc.
Equities
LUCD
US54948X1090
Medical Equipment, Supplies & Distribution
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.688 USD | +0.72% |
|
-8.10% | -51.06% |
| Mar. 27 | Cantor Fitzgerald Trims Price Target on Lucid Diagnostics to $3 From $3.80, Maintains Overweight Rating | MT |
| Mar. 26 | Transcript : Lucid Diagnostics Inc., Q4 2023 Earnings Call, Mar 26, 2024 |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 197.7 | 53.19 | 59.69 | 32.96 | - | - |
| Enterprise Value (EV) 1 | 197.7 | 53.19 | 59.69 | 32.96 | 32.96 | 32.96 |
| P/E ratio | -3.56 x | -0.88 x | -1.12 x | -0.68 x | -0.82 x | -1.29 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 395 x | 141 x | 24.6 x | 5.75 x | 2 x | 0.73 x |
| EV / Revenue | 395 x | 141 x | 24.6 x | 5.75 x | 2 x | 0.73 x |
| EV / EBITDA | -7.21 x | -0.98 x | -1.3 x | -0.81 x | -0.91 x | -0.96 x |
| EV / FCF | -10.7 x | -1.74 x | - | -0.81 x | -1.09 x | -2.39 x |
| FCF Yield | -9.37% | -57.5% | - | -123% | -91.7% | -41.9% |
| Price to Book | 3.43 x | 2.39 x | - | -0.82 x | -0.46 x | - |
| Nbr of stocks (in thousands) | 36,809 | 39,108 | 42,330 | 48,245 | - | - |
| Reference price 2 | 5.370 | 1.360 | 1.410 | 0.6831 | 0.6831 | 0.6831 |
| Announcement Date | 3/28/22 | 3/14/23 | 3/25/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.5 | 0.377 | 2.428 | 5.733 | 16.48 | 45.15 |
| EBITDA 1 | - | -27.42 | -54.24 | -45.98 | -40.85 | -36.2 | -34.47 |
| EBIT 1 | - | -27.42 | -56.17 | -48.48 | -45.37 | -40.92 | -27.57 |
| Operating Margin | - | -5,483.8% | -14,899.47% | -1,996.79% | -791.32% | -248.35% | -61.06% |
| Earnings before Tax (EBT) 1 | - | -28.08 | -56.17 | -52.67 | -46.68 | -44.95 | -42 |
| Net income 1 | -8.28 | -28.08 | -56.17 | -52.67 | -46.97 | -42.59 | -40.87 |
| Net margin | - | -5,615.6% | -14,899.47% | -2,169.11% | -819.22% | -258.46% | -90.52% |
| EPS 2 | -0.5882 | -1.510 | -1.550 | -1.260 | -0.9980 | -0.8320 | -0.5275 |
| Free Cash Flow 1 | - | -18.53 | -30.59 | - | -40.62 | -30.22 | -13.81 |
| FCF margin | - | -3,706% | -8,114.85% | - | -708.55% | -183.41% | -30.59% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 9/22/21 | 3/28/22 | 3/14/23 | 3/25/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.2 | 0.3 | 0.189 | - | 0.076 | 0.112 | 0.446 | 0.159 | 0.783 | 1.04 | 1.046 | 1.292 | 1.556 | 1.868 | 1.633 |
| EBITDA 1 | -6.51 | -11.24 | -12.25 | -13.92 | -13.76 | -14.31 | -15.68 | -10.66 | -13.55 | -10.82 | -9.925 | -10.35 | -10.3 | -10.28 | -9.867 |
| EBIT 1 | -6.566 | -11.24 | -12.77 | -14.62 | -14.35 | -14.93 | -14.32 | -11.58 | -11.13 | -11.45 | -11.36 | -11.29 | -11.32 | -11.4 | -11.47 |
| Operating Margin | -3,283% | -3,747% | -6,756.61% | - | -18,880.26% | -13,328.57% | -3,210.09% | -7,285.53% | -1,421.2% | -1,101.25% | -1,085.76% | -873.78% | -727.19% | -610.05% | -702.04% |
| Earnings before Tax (EBT) 1 | -7.013 | -11.31 | -12.27 | -14.62 | -14.35 | -14.93 | -16.25 | -11.38 | -14.21 | -10.83 | -11.53 | -11.64 | -11.67 | -11.81 | -12.15 |
| Net income 1 | -6.957 | -11.31 | -12.27 | -14.62 | -14.35 | -14.93 | -16.25 | -11.38 | -14.21 | -10.83 | -11.73 | -11.73 | -11.72 | -11.8 | -12.3 |
| Net margin | -3,478.5% | -3,768.67% | -6,492.06% | - | -18,880.26% | -13,328.57% | -3,642.83% | -7,157.86% | -1,814.56% | -1,041.35% | -1,120.81% | -907.31% | -752.89% | -631.46% | -753.06% |
| EPS 2 | -0.4900 | -0.3200 | -0.3500 | -0.4100 | -0.3900 | -0.4000 | -0.4000 | -0.2700 | -0.3400 | -0.2500 | -0.2680 | -0.2480 | -0.2440 | -0.2420 | -0.2500 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/16/21 | 3/28/22 | 5/11/22 | 8/15/22 | 11/14/22 | 3/14/23 | 5/15/23 | 8/14/23 | 11/13/23 | 3/25/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -18.5 | -30.6 | - | -40.6 | -30.2 | -13.8 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 1.570 | 0.5700 | - | -0.8300 | -1.490 | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | 0.86 | 0.91 | - | 1.41 | 2.37 | 4.07 |
| Capex / Sales | - | 172.4% | 240.85% | - | 24.68% | 14.39% | 9% |
| Announcement Date | 9/22/21 | 3/28/22 | 3/14/23 | 3/25/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.6831
USD
Average target price
3.833
USD
Spread / Average Target
+461.17%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -51.06% | 32.96M | |
| +73.09% | 12.38B | |
| -18.54% | 7.92B | |
| +17.23% | 7.2B | |
| +6.82% | 5.84B | |
| +5.99% | 5.07B | |
| +27.07% | 4.53B | |
| -21.67% | 3.88B | |
| -41.94% | 2.23B | |
| +0.99% | 2.02B |
- Stock Market
- Equities
- LUCD Stock
- Financials Lucid Diagnostics Inc.
